Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13589510 | 0.82 | PTGS2 (0.50) | GHSRENPP2TGM2CA12CA1 | |
| SCHEMBL11149031 | 0.82 | CA1 (0.46) | CA12CA1CA2CA9CA5A | |
| Sulfuric Acid SCHEMBL30019534 | 0.81 | CA12 (0.43) | CA12CA1CA2CA9CA5A | |
| SCHEMBL13589540 | 0.81 | CA1 (0.45) | GHSRENPP2TGM2CA12CA1 | |
| SCHEMBL5969283 | 0.81 | GHSR (0.37) | GHSRENPP2CA12CA1CA2 | |
| SCHEMBL6150769 | 0.81 | CA1 (0.45) | GHSRENPP2TGM2CA12CA1 | |
| SCHEMBL27540686 | 0.81 | CA2 (0.62) | CA12CA1CA2CA9CA5A | |
| SCHEMBL9682966 | 0.81 | FLT3 (0.46) | TGM2ESR2PTGS2 | |
| SCHEMBL13588723 | 0.80 | CA1 (0.45) | CA12CA1CA2CA9CA5A | |
| SCHEMBL5923863 | 0.79 | PTGS2 (0.52) | GHSRCA1CA2CA9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010024356-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE HAVING NAPHTHYRIDINE-N-OXIDE | 大正製薬株式会社 (JP) | 2010-03-04 | — | — | WO | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | GHSR 1562/4885ENPP2 1210/4885TGM2 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.